ArticleFrontiers in pharmacology2026
Impact of bromocriptine withdrawal timing on pregnancy outcomes in patients with pituitary prolactin-secreting microadenomas: a real-world retrospective study of 188 pregnancies in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to evaluate the influence of the timing for bromocriptine withdrawal in pregnant women with pituitary prolactin-secreting microadenomas. Methods: In this retrospective study,188 pregnant women diagnosed with pituitary prolactin-secreting microadenomas, who delivered between January 2005 and June 2023 were categorized into four groups based on their use and duration of bromocriptine therapy. Their pregnancy and neonatal outcomes were analyzed. Results: Among the 188 patients, the incidence of neurological symptoms during pre-pregnancy varied significantly across the groups (P = 0.000), with the highest prevalence in Group A (21.7%) and minimal to no symptoms in other Groups. The live birth rates and miscarriage rates did not show statistically significant differences across the groups (P = 0.508). Premature birth rates were 6.5%, 6.2%, 13.2%, and 0% for Groups A, B, C, and D, respectively. Notably, the incidence of small-for-gestational-age (SGA) infants increased with prolonged bromocriptine use, while large-for-gestational-age (LGA) rates decreased, though these trends were not statistically significant (P = 0.068). Median gestational age differed significantly across groups (P = 0.000), but neonatal weights remained comparable (P = 0.471). Conclusion: Discontinuation of bromocriptine after pregnancy confirmation is generally safe for patients with pituitary prolactin-secreting microadenomas. However, for patients with pre-existing neurological or ophthalmological symptoms, or those untreated prior to pregnancy, close monitoring and potential continuation of dopamine agonist therapy are waranted. Bromocriptine exposure throughout pregnancy does not increase the risk of miscarriage, congenital anomalies, or adverse neonatal outcomes. But further prospective studies are needed to elucidate the long-term effects of bromocriptine on fetal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.